IN2014CN00614A - - Google Patents
Info
- Publication number
- IN2014CN00614A IN2014CN00614A IN614CHN2014A IN2014CN00614A IN 2014CN00614 A IN2014CN00614 A IN 2014CN00614A IN 614CHN2014 A IN614CHN2014 A IN 614CHN2014A IN 2014CN00614 A IN2014CN00614 A IN 2014CN00614A
- Authority
- IN
- India
- Prior art keywords
- human ngf
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011176209 | 2011-08-11 | ||
JP2011269215 | 2011-12-08 | ||
PCT/JP2012/070433 WO2013022083A1 (ja) | 2011-08-11 | 2012-08-10 | 新規抗ヒトngf抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN00614A true IN2014CN00614A (sl) | 2015-04-03 |
Family
ID=47668585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN614CHN2014 IN2014CN00614A (sl) | 2011-08-11 | 2012-08-10 |
Country Status (28)
Country | Link |
---|---|
US (2) | US8986952B2 (sl) |
EP (1) | EP2743348B1 (sl) |
JP (1) | JP5376095B2 (sl) |
KR (1) | KR101999867B1 (sl) |
CN (1) | CN103748222B (sl) |
AR (1) | AR087506A1 (sl) |
AU (1) | AU2012293161B2 (sl) |
BR (1) | BR112014002576B1 (sl) |
CA (1) | CA2841181C (sl) |
CY (1) | CY1119914T1 (sl) |
DK (1) | DK2743348T3 (sl) |
EA (1) | EA024292B1 (sl) |
ES (1) | ES2663968T3 (sl) |
HR (1) | HRP20180155T1 (sl) |
HU (1) | HUE036079T2 (sl) |
IL (1) | IL230797A (sl) |
IN (1) | IN2014CN00614A (sl) |
LT (1) | LT2743348T (sl) |
ME (1) | ME02944B (sl) |
MX (1) | MX351273B (sl) |
NO (1) | NO2743348T3 (sl) |
PL (1) | PL2743348T3 (sl) |
PT (1) | PT2743348T (sl) |
RS (1) | RS56876B1 (sl) |
SI (1) | SI2743348T1 (sl) |
TW (1) | TWI554519B (sl) |
WO (1) | WO2013022083A1 (sl) |
ZA (1) | ZA201400741B (sl) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
CA2821515A1 (en) | 2010-12-01 | 2012-06-07 | Alder Biopharmaceuticals, Inc. | Anti-ngf compositions and use thereof |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトngf抗体 |
MX2017014911A (es) * | 2015-05-22 | 2018-03-23 | Astellas Pharma Inc | Fragmento fab de anticuerpo ngf anti-humano novedoso. |
CN108883177A (zh) * | 2016-03-25 | 2018-11-23 | 安斯泰来制药株式会社 | 含有PEG化抗人NGF抗体Fab’片段的药物组合物 |
CN114751982B (zh) * | 2017-12-15 | 2023-06-23 | 安源医药科技(上海)有限公司 | 抗人ngf抗体及其制备方法和用途 |
EP3795176A4 (en) | 2018-05-15 | 2022-01-12 | Astellas Pharma Inc. | PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JP3855071B2 (ja) * | 1993-03-11 | 2006-12-06 | 財団法人化学及血清療法研究所 | 抗hivモノクローナル抗体 |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CA2448956C (en) | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
SI2263692T1 (sl) | 2002-12-24 | 2020-10-30 | Rinat Neuroscience Corp. | Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo |
EP2364728A1 (en) | 2003-07-15 | 2011-09-14 | Amgen, Inc | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
US9315571B2 (en) | 2005-01-24 | 2016-04-19 | Elan Pharma International Limited | Specific binding members for NGF |
ME00977B (me) * | 2007-08-10 | 2012-06-20 | Regeneron Pharma | Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
RU2461551C2 (ru) | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
UY32608A (es) | 2009-05-04 | 2010-12-31 | Pangenetics 110 B V | Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada |
-
2012
- 2012-08-10 SI SI201231222T patent/SI2743348T1/sl unknown
- 2012-08-10 IN IN614CHN2014 patent/IN2014CN00614A/en unknown
- 2012-08-10 HU HUE12821758A patent/HUE036079T2/hu unknown
- 2012-08-10 RS RS20180173A patent/RS56876B1/sr unknown
- 2012-08-10 PL PL12821758T patent/PL2743348T3/pl unknown
- 2012-08-10 CA CA2841181A patent/CA2841181C/en active Active
- 2012-08-10 BR BR112014002576-2A patent/BR112014002576B1/pt not_active IP Right Cessation
- 2012-08-10 TW TW101128963A patent/TWI554519B/zh active
- 2012-08-10 JP JP2013525474A patent/JP5376095B2/ja not_active Expired - Fee Related
- 2012-08-10 ES ES12821758.5T patent/ES2663968T3/es active Active
- 2012-08-10 WO PCT/JP2012/070433 patent/WO2013022083A1/ja active Application Filing
- 2012-08-10 EA EA201490433A patent/EA024292B1/ru not_active IP Right Cessation
- 2012-08-10 AR ARP120102927 patent/AR087506A1/es active IP Right Grant
- 2012-08-10 LT LTEP12821758.5T patent/LT2743348T/lt unknown
- 2012-08-10 KR KR1020147003155A patent/KR101999867B1/ko active IP Right Grant
- 2012-08-10 PT PT128217585T patent/PT2743348T/pt unknown
- 2012-08-10 EP EP12821758.5A patent/EP2743348B1/en active Active
- 2012-08-10 MX MX2014001627A patent/MX351273B/es active IP Right Grant
- 2012-08-10 US US13/879,267 patent/US8986952B2/en active Active
- 2012-08-10 NO NO12821758A patent/NO2743348T3/no unknown
- 2012-08-10 AU AU2012293161A patent/AU2012293161B2/en not_active Ceased
- 2012-08-10 CN CN201280039293.3A patent/CN103748222B/zh active Active
- 2012-08-10 ME MEP-2018-28A patent/ME02944B/me unknown
- 2012-08-10 DK DK12821758.5T patent/DK2743348T3/en active
-
2014
- 2014-01-30 ZA ZA2014/00741A patent/ZA201400741B/en unknown
- 2014-02-03 IL IL230797A patent/IL230797A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/596,874 patent/US20150218265A1/en not_active Abandoned
-
2018
- 2018-01-26 HR HRP20180155TT patent/HRP20180155T1/hr unknown
- 2018-02-14 CY CY20181100180T patent/CY1119914T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN00614A (sl) | ||
NZ706377A (en) | Il-6 antagonists and uses thereof | |
NZ603499A (en) | Human cytomegalovirus neutralizing antibodies and uses thereof | |
NZ703653A (en) | Anti-fap antibodies and methods of use | |
NZ611468A (en) | Humanized antibodies to liv-1 and use of same to treat cancer | |
MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
NI201200171A (es) | Anticuerpos hacia gdf8 humano | |
NZ610734A (en) | Human antibodies to the glucagon receptor | |
CY1118551T1 (el) | Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4 | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
NZ701444A (en) | Antibodies to matrix metalloproteinase 9 | |
MX2014001371A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
MY177098A (en) | Novel anti-human tslp receptor antibody | |
NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
MY185811A (en) | Novel anti-human tie-2 antibody | |
MX2012000316A (es) | Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. | |
NZ595792A (en) | Antibodies specific to cadherin-17 | |
JOP20190103A1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
AU2012315616A8 (en) | Identification of antigen-specific adaptive immune responses using Arm-PCR and high-throughput sequencing | |
MX347955B (es) | Novedoso anticuerpo anti-receptor de il-23 humano. | |
EA201491240A1 (ru) | Новое антитело против ctgf человека | |
NZ594452A (en) | Anti-mst1r antibodies and uses thereof | |
MX2018011039A (es) | Podocalixina y anticuerpos relacionados con tra, metodos de preparacion y usos como agente terapeutico anticancerigeno. |